Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform ...

FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield (Reuters) -AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed ...

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies “Engineered T cell therapies have demonstrated ...

SANTA MONICA, Calif. & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully individualized T cell receptor (TCR) therapies ...

Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of ...

Nov 29 (Reuters) - AstraZeneca AZN.L said on Tuesday it would acquire Neogene Therapeutics, a developer of cell-based cancer treatments, for up to $320 million, as the London-listed drugmaker seeks to ...

AstraZeneca expanded its oncology portfolio Tuesday morning by announcing it reached an agreement to buy Neogene Therapeutics. The British pharma giant is purchasing the clinical-stage biotechnology ...

Raphaël Rousseau, M.D., Ph.D., is the latest biopharma vet to land at transatlantic biotech Neogene Therapeutics, where he joins a leadership bench of Kite and Bristol Myers Squibb veterans. Rousseau ...

Neogene aims to begin Phase I clinical studies in 2022. Neogene Therapeutics Inc. has raised $110 million in financing to advance the development of neo-antigen T cell therapies to treat various types ...

NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...